Clinical Trial Update: Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 [Phase 3]

View source ↗

Summary

Phase 3 trial update of a recombinant Bet v 1 allergen assessing efficacy and safety in birch pollen allergy. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Birch Pollen Allergy

Drugs mentioned

• Bet v 1 recombinant allergen (recombinant Bet v 1 allergen)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Allergy | Phase 3 | Status: COMPLETED